Patent ID: 8138199

Claim:
A method of inhibiting JAK2 kinase activity in a subject wherein the subject has a myeloproliferative disorder, comprising administering to the subject with a myeloproliferative disorder an effective amount of a compound having the structure (A): wherein: X is selected from a group consisting of a bond, O and CH 2 ; Y is selected from a group consisting of a bond or NR 9 ; or X and Y taken together is a bond; each of R 1 and R 2 is independently selected from a group consisting of H, C 1 -C 6 alkyl, cycloalkyl, or R 1 and R 2 taken together is a bond; or R 1 and R 2 taken together form a moiety selected from a group consisting of (CH 2 ) m , (CH 2 ) r —S—(CH 2 ) m , (CH 2 ) r —SO—(CH 2 ) m , (CH 2 ) r —SO 2 —(CH 2 ) m , (CH 2 ) r —NR 9 —(CH 2 ) m , and (CH 2 ) r —O—(CH 2 ) m ; each of p, q, r, n, m is independently an integer having the value between 0 and 6, each R 9 is independently selected from a group consisting of H, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, C 3 -C 6 branched alkyl, C 1 -C 6 aminoalkyl, and C 1 -C 6 hydroxyalkyl; G 0 is selected from a group consisting of N and CH, each G is independently CR 6 or C when bonded to X; R 5 is methyl; each of R 6 , R 7 and R 8 is independently selected from a group consisting of H, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 6 hydroxyalkyl or aminoalkyl, C 3 -C 6 cycloalkyl, a halogen, CF 3 , OCF 3 , SO 2 H, SO 2 (C 1 -C 6 alkyl), SO 2 -heterocycle, SO 2 -cycloalkyl, SO 2 N(C 1 -C 6 alkyl)H, SO 2 N(C 1 -C 6 alkyl)(C 1 -C 6 alkyl), SO 2 NH(C 3 -C 6 cycloalkyl), SO 2 NH-heterocycle, (SO 2 N(C 3 -C 6 branched alkyl)H, NO 2 , CN, CONH 2 , CO—(C 1 -C 6 alkyl), COOH, COO—(C 1 -C 6 alkyl), and NHCO—(C 1 -C 6 alkyl), or R 6 and R 7 taken together, or R 7 and R 8 , taken together, form a moiety independently selected from the group consisting of —CH═CH—CH═CH—, and —O—(CH 2 ) n —O—; A is selected from a group consisting of NH, and N—(C 1 -C 6 alkyl); G 1 is CH; G 2 is CR 7 , with each group R 7 being independent of every other group R 7 ; and R 3 and R 4 are taken together with G 0 to form a heterocyclic ring system; wherein alkyl, alkenyl, alkynyl, cycloalkyl, or heterocycle, for each occurrence if any, are optionally substituted by one or more substituents selected from the group consisting of hydroxy, alkoxy, mercapto, halogen, cyano, nitro, amino, amido, aldehyde, acyl, oxyacyl, carboxyl, sulfonyl, sulfonamide, or sulfuryl; or a pharmaceutically acceptable salt thereof.